Adriano Chiò1, Cristina Moglia2, Antonio Canosa2, Umberto Manera2, Rosario Vasta2, Maura Brunetti2, Marco Barberis2, Lucia Corrado2, Sandra D'Alfonso2, Enrica Bersano2, Maria Francesca Sarnelli2, Valentina Solara2, Jean Pierre Zucchetti2, Laura Peotta2, Barbara Iazzolino2, Letizia Mazzini2, Gabriele Mora2, Andrea Calvo2. 1. From the ALS Center (A. Chiò, C.M., A. Canosa, U.M., R.V., M. Brunetti, M. Barberis, J.P.Z., L.P., B.I., A. Calvo), "Rita Levi Montalcini" Department of Neuroscience, University of Torino; Azienda Ospedaliero-Universitaria Città della Salute e della Scienza of Torino (A. Chiò, C.M., A. Calvo), Turin; Institute of Cognitive Sciences and Technologies (A. Chiò), National Research Council, Rome; Department of Health Sciences Interdisciplinary Research Center of Autoimmune Diseases (L.C., S.D.), "Amedeo Avogadro" University of Eastern Piedmont; ALS Center (E.B., M.F.S., V.S., L.M.), Department of Neurology, Azienda Ospedaliera Universitaria Maggiore della Carità, Novara; and Istituti Clinici Scientifici Maugeri (G.M.), IRCCS Milano, Milan, Italy. adriano.chio@unito.it. 2. From the ALS Center (A. Chiò, C.M., A. Canosa, U.M., R.V., M. Brunetti, M. Barberis, J.P.Z., L.P., B.I., A. Calvo), "Rita Levi Montalcini" Department of Neuroscience, University of Torino; Azienda Ospedaliero-Universitaria Città della Salute e della Scienza of Torino (A. Chiò, C.M., A. Calvo), Turin; Institute of Cognitive Sciences and Technologies (A. Chiò), National Research Council, Rome; Department of Health Sciences Interdisciplinary Research Center of Autoimmune Diseases (L.C., S.D.), "Amedeo Avogadro" University of Eastern Piedmont; ALS Center (E.B., M.F.S., V.S., L.M.), Department of Neurology, Azienda Ospedaliera Universitaria Maggiore della Carità, Novara; and Istituti Clinici Scientifici Maugeri (G.M.), IRCCS Milano, Milan, Italy.
Abstract
OBJECTIVE: To assess the association of the degree of severity of motor impairment to that of cognitive impairment in a large cohort of patients with amyotrophic lateral sclerosis (ALS). METHODS: This is a population-based cross-sectional study on patients with ALS incident in Piemonte, Italy, between 2007 and 2015. Cognitive status was classified according to the revised ALS-FTD Consensus Criteria. The King system and the Milano Torino Staging system (MiToS) were used for defining the severity of motor impairment. RESULTS: Of the 797 patients included in the study, 163 (20.5%) had ALS-frontotemporal dementia (FTD), 38 (4.8%) cognitive and behavioral impairment (ALScbi), 132 (16.6%) cognitive impairment (ALSci), 63 (7.9%) behavioral impairment (ALSbi), 16 (2.0%) nonexecutive impairment, and 385 (48.2%) were cognitively normal. According to King staging, the frequency of cases with ALS-FTD progressively increased from 16.5% in stage 1-44.4% in stage 4; conversely, the frequency of ALSci, ALSbi, and ALScbi increased from King stage 1 to King stage 3 and decreased thereafter. A similar pattern was observed with the MiToS staging. ALS-FTD was more frequent in patients with bulbar involvement at time of cognitive testing. Patients with C9ORF72 expansion (n = 61) showed more severe cognitive impairment with increasing King and MiToS stages. CONCLUSION: Our findings suggest that ALS motor and cognitive components may worsen in parallel, and that cognitive impairment becomes more pronounced when bulbar function is involved. Our data support the hypothesis that ALS pathology disseminates in a regional ordered sequence, through a cortico-efferent spreading model.
OBJECTIVE: To assess the association of the degree of severity of motor impairment to that of cognitive impairment in a large cohort of patients with amyotrophic lateral sclerosis (ALS). METHODS: This is a population-based cross-sectional study on patients with ALS incident in Piemonte, Italy, between 2007 and 2015. Cognitive status was classified according to the revised ALS-FTD Consensus Criteria. The King system and the Milano Torino Staging system (MiToS) were used for defining the severity of motor impairment. RESULTS: Of the 797 patients included in the study, 163 (20.5%) had ALS-frontotemporal dementia (FTD), 38 (4.8%) cognitive and behavioral impairment (ALScbi), 132 (16.6%) cognitive impairment (ALSci), 63 (7.9%) behavioral impairment (ALSbi), 16 (2.0%) nonexecutive impairment, and 385 (48.2%) were cognitively normal. According to King staging, the frequency of cases with ALS-FTD progressively increased from 16.5% in stage 1-44.4% in stage 4; conversely, the frequency of ALSci, ALSbi, and ALScbi increased from King stage 1 to King stage 3 and decreased thereafter. A similar pattern was observed with the MiToS staging. ALS-FTD was more frequent in patients with bulbar involvement at time of cognitive testing. Patients with C9ORF72 expansion (n = 61) showed more severe cognitive impairment with increasing King and MiToS stages. CONCLUSION: Our findings suggest that ALS motor and cognitive components may worsen in parallel, and that cognitive impairment becomes more pronounced when bulbar function is involved. Our data support the hypothesis that ALS pathology disseminates in a regional ordered sequence, through a cortico-efferent spreading model.
Authors: Johannes Brettschneider; Kelly Del Tredici; Jon B Toledo; John L Robinson; David J Irwin; Murray Grossman; EunRan Suh; Vivianna M Van Deerlin; Elisabeth M Wood; Young Baek; Linda Kwong; Edward B Lee; Lauren Elman; Leo McCluskey; Lubin Fang; Simone Feldengut; Albert C Ludolph; Virginia M-Y Lee; Heiko Braak; John Q Trojanowski Journal: Ann Neurol Date: 2013-06-19 Impact factor: 10.422
Authors: Elisabeth Kasper; Kolja Zydatiss; Christina Schuster; Judith Machts; Daniel Bittner; Jörn Kaufmann; Reiner Benecke; Stefan Vielhaber; Stefan Teipel; Johannes Prudlo Journal: Neurodegener Dis Date: 2015-11-28 Impact factor: 2.977
Authors: David J Irwin; Corey T McMillan; Johannes Brettschneider; David J Libon; John Powers; Katya Rascovsky; Jon B Toledo; Ashley Boller; Jonathan Bekisz; Keerthi Chandrasekaran; Elisabeth McCarty Wood; Leslie M Shaw; John H Woo; Philip A Cook; David A Wolk; Steven E Arnold; Vivianna M Van Deerlin; Leo F McCluskey; Lauren Elman; Virginia M-Y Lee; John Q Trojanowski; Murray Grossman Journal: J Neurol Neurosurg Psychiatry Date: 2012-10-31 Impact factor: 10.154
Authors: Chris J Gibbons; Roger J Mills; Everard W Thornton; John Ealing; John D Mitchell; Pamela J Shaw; Kevin Talbot; Alan Tennant; Carolyn A Young Journal: Health Qual Life Outcomes Date: 2011-09-29 Impact factor: 3.186
Authors: Judith Machts; Verena Bittner; Elisabeth Kasper; Christina Schuster; Johannes Prudlo; Susanne Abdulla; Katja Kollewe; Susanne Petri; Reinhard Dengler; Hans-Jochen Heinze; Stefan Vielhaber; Mircea A Schoenfeld; Daniel M Bittner Journal: BMC Neurosci Date: 2014-06-30 Impact factor: 3.288
Authors: Laura Carelli; Federica Solca; Andrea Faini; Paolo Meriggi; Davide Sangalli; Pietro Cipresso; Giuseppe Riva; Nicola Ticozzi; Andrea Ciammola; Vincenzo Silani; Barbara Poletti Journal: Biomed Res Int Date: 2017-08-23 Impact factor: 3.411
Authors: Jose C Roche; Ricardo Rojas-Garcia; Kirsten M Scott; William Scotton; Catherine E Ellis; Rachel Burman; Lokesh Wijesekera; Martin R Turner; P Nigel Leigh; Christopher E Shaw; Ammar Al-Chalabi Journal: Brain Date: 2012-01-23 Impact factor: 13.501
Authors: M M El Mendili; A-M Grapperon; R Dintrich; J-P Stellmann; J-P Ranjeva; M Guye; A Verschueren; S Attarian; W Zaaraoui Journal: AJNR Am J Neuroradiol Date: 2022-06-30 Impact factor: 4.966
Authors: Colin J Mahoney; Rebekah M Ahmed; William Huynh; Sicong Tu; Jonathan D Rohrer; Richard S Bedlack; Orla Hardiman; Matthew C Kiernan Journal: CNS Drugs Date: 2021-05-15 Impact factor: 5.749